Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapy

Medical Hypotheses

Volumn 57, Issue 2, 2001, Pages 216-220

  McCarty, M F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; BEZAFIBRATE; BLOOD CLOTTING FACTOR 7; ESTROGEN; LIPID; PROTEIN S; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ANTICOAGULATION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; HEART INFARCTION; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE; SUSTAINED RELEASE PREPARATION; THROMBOEMBOLISM; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 0034918676     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.2000.1314     Document Type: Article

References (77)

1. Cardioprotection by estrogens: Implications of observational studies
2. Postmenopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins
3. Effects of sex steroids on serum lipids and lipoproteins
4. Increased expression of endothelial constitutive nitric oxide synthase in rat aorta during pregnancy
5. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986
6. Estrogens increase transcription of the human endothelial NO synthase gene: Analysis of the transcription factors involved
7. Estradiol induces the calcium dependent translocation of endothelial nitric oxide synthase
8. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women
9. Estrogen improves endothelial function
10. Cardioprotection by estrogens: Mechanisms of action-the lipids
11. Estrogen replacement therapy and cardiovascular protection: Lipid mechanisms are the tip of an iceberg
12. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: A review
13. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women
14. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause
15. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study
16. HRT and breast cancer risk: A clue for interpreting the available data
17. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis
18. Estrogen replacement therapy and colorectal cancer risk in elderly women
19. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
20. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women
21. The androgenicity of progestins
22. Lipid profile during hormone replacement therapy: Effect of different progestins?
23. Effect of progestins on IGF-I serum level in estrogen-treated postmenopausal women
24. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis
25. Estrogens, progestins, and coronary artery reactivity in atherosclerotic monkeys
26. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys
27. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men
28. Micronized progesterone: A new therapeutic option
29. Micronized progesterone: Clinical indications and comparison with current treatments
30. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study
31. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
32. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study
33. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
34. Coagulation activation following estrogen administration to postmenopausal women
35. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
36. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial
37. Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women
38. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status
39. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: Relation to the development of cardiovascular disease
40. The effect of hormone replacement therapy of the age-related rise of factor VIIc, and its activity state
41. Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy
42. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study
43. Oral versus transdermal hormone replacement therapy
44. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: No additional unfavourable effects of dydrogesterone
45. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism
46. Effects of endurance exercise and hormone replacement therapy on serum lipids in older women
47. How HRT alters the lipid profile in women with diabetes
48. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity
49. Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: Lack of threshold value
50. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: A study in familial lipoprotein-lipase deficiency
51. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency
52. The link between high-fat meals and postprandial activation of blood coagulation factor VII possibly involves kallikrein
53. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
54. The menopause and hormone replacement therapy: Lipids, lipoproteins, coagulation and fibrinolytic factors
55. Effects of low dosage progestin-only administration upon plasma triglycerides and lipoprotein metabolism in postmenopausal women
56. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia
57. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia
58. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action
59. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs
60. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia
61. Bezafibrate down-regulates fibrinogen biosynthesis in human hepatoma HepG2 cells
62. Serum insulin-like growth factor-1 level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: Beneficial effects of bezafibrate treatment
63. Secondary preventive potential of lipid-lowering drugs
64. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
65. Comparative review of third-generation progestins
66. Chemoprevention of radiation-induced mammary tumors in rats by bezafibrate administered together with diethylstilbestrol as a promoter
67. Western nutrition and the insulin resistance syndrome: A link to breast cancer
68. Gemfibrozil reduces plasma prothrombin fragment F1 + 2 concentration, a marker of coagulability, in patients with coronary heart disease
69. Sesamin, a sesame lignan, is a potent inducer of hepatic fatty acid oxidation in the rat
70. Phytol and peroxisome proliferation
71. Influence of n-6 versus n-3 polyunsaturated fatty acids in diets low in saturated fatty acids on plasma lipoproteins and hemostatic factors
72. Effects of diet composition on coagulation pathways
73. Effect of omega-3 fatty acids and simvastation on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia
74. Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia
75. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia
76. Effectiveness of long-term treatment with pantethine in patients with dyslipidemia
77. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: Adults and children